Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma: Data from an open-label, multicenter phase II basket study.

被引：0
|
作者：
Chen, Ming-Yuan
Chen, Xiaozhong
Zhang, Ximei
Liu, Tianshu
Wang, Xicheng
Cai, Jinling
Wang, Shuni
Chen, Chunxia
Fan, Jia
机构：
[1] Sun Yat Sen Univ, Dept Nasopharyngeal Carcinoma, Canc Ctr, Guangzhou, Peoples R China
[2] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Head & Neck Tumor Radiotherapy, Hangzhou, Peoples R China
[3] Tianjin Med Univ, Canc Inst & Hosp, Dept Radiotherapy, Tianjin, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China
[5] Guangdong Pharmaceut Univ, Affiliated Hosp 1, Sch Clin Med, Guangzhou, Peoples R China
[6] Jiangsu Hengrui Pharmaceut Co Ltd, Clin Res & Dev, Shanghai, Peoples R China
[7] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18031
引用
收藏
页码：E18031 / E18031
页数：1
相关论文
共 50 条
  • [1] Camrelizumab plus famitinib in patients with metastatic colorectal cancer: Results from an open-label, multicenter phase II basket study.
    Liu, Tianshu
    Yang, Mudan
    Li, Jin
    Pan, Yueyin
    Yuan, Ying
    Yi, Shanyong
    Wang, Junsheng
    Cheng, Ying
    Feng, Jifeng
    Gao, Shegan
    Wang, Xicheng
    Qu, Song
    Zhang, Xizhi
    Lu, Jin
    Xiu, Peng
    Wang, Shuni
    Yang, Xinfeng
    Fan, Jia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study
    Qu, Yuan-Yuan
    Zhang, Hai-Liang
    Guo, Hongqian
    Luo, Hong
    Zou, Qing
    Xing, Nianzeng
    Xia, Shujie
    Sun, Zhongquan
    Zhang, Xuepei
    He, Chaohong
    Cai, Jinling
    Zhang, Xiao
    Wang, Quanren
    Ye, Ding-Wei
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (21) : 5838 - 5846
  • [3] Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
    Ding, Xi
    Zhang, Wei-Jing
    You, Rui
    Zou, Xiong
    Wang, Zhi-Qiang
    Ouyang, Yan-Feng
    Peng, Lan
    Liu, You-Ping
    Duan, Chong-Yang
    Yang, Qi
    Lin, Chao
    Xie, Yu-Long
    Chen, Si-Yuan
    Liu, Yong-Long
    Gu, Chen-Mei
    Xie, Ruo-Qi
    Huang, Pei-Yu
    Hong, Ming-Huang
    Hua, Yi-Jun
    Chen, Ming-Yuan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2571 - +
  • [4] Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study
    Ren, Shengxiang
    Xiong, Anwen
    Yu, Jia
    Wang, Xicheng
    Han, Baohui
    Pan, Yueyin
    Zhao, Jun
    Cheng, Yufeng
    Hu, Sheng
    Liu, Tianshu
    Li, Yalun
    Cheng, Ying
    Feng, Jifeng
    Yi, Shanyong
    Gu, Shanzhi
    Gao, Shegan
    Luo, Yongzhong
    Liu, Ying
    Liu, Caigang
    Duan, Huijie
    Wang, Shuni
    Yang, Xinfeng
    Fan, Jia
    Zhou, Caicun
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (07)
  • [5] Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study
    Ding, Xi
    Hua, Yi-Jun
    Zou, Xiong
    Chen, Xiao-Zhong
    Zhang, Xi-Mei
    Xu, Bei
    Ouyang, Yan-Feng
    Tu, Zi-Wei
    Li, Hui-Feng
    Duan, Chong-Yang
    Zhang, Wei-Jing
    You, Rui
    Liu, You-Ping
    Liu, Yong-Long
    Yang, Qi
    Huang, Pei-Yu
    Wang, Shu-Ni
    Fan, Jia
    Chen, Ming-Yuan
    [J]. ECLINICALMEDICINE, 2023, 61
  • [6] Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma failing first-line therapy: An open-label, single-arm, phase II study
    Ding, X.
    Zhang, W.
    You, R.
    Zou, X.
    Wang, Z.
    Ouyang, Y-F.
    Liu, Y-L.
    Peng, L.
    You-Ping, L.
    Duan, C-Y.
    Yang, Q.
    Lin, C.
    Yulong, X.
    Chen, S-Y.
    Gu, C-M.
    Huang, P. Y.
    Hua, Y.
    Chen, M.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S846 - S846
  • [7] Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open- label, multicenter phase 2 basket study
    Xia, Lingfang
    Peng, Jin
    Lou, Ge
    Pan, Mei
    Zhou, Qi
    Hu, Wenjing
    Shi, Huirong
    Wang, Li
    Gao, Yunong
    Zhu, Jianqing
    Zhang, Yu
    Sun, Rong
    Zhou, Xianfeng
    Wang, Quanren
    Wu, Xiaohua
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
  • [8] A phase II, multicenter, open-label, single-arm trial of famitinib in patients with advanced recurrent and/or metastatic nasopharyngeal carcinoma (NPC) after two previous treatment regimens
    Huang, Yan
    Zhang, Li
    Pan, Jian-ji
    Hu, Guoqing
    Gang, Wu
    Xiong, Jian Ping
    Hu, Chaosu
    Lin, Lizhu
    Yu, Hao
    Jiang, Haoyuan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma
    Lingfang Xia
    Qi Zhou
    Yunong Gao
    Wenjing Hu
    Ge Lou
    Hong Sun
    Jianqing Zhu
    Jin Shu
    Xianfeng Zhou
    Rong Sun
    Xiaohua Wu
    [J]. Nature Communications, 13 (1)
  • [10] Camrelizumab plus famitinib as first-line treatment in advanced NSCLC patients with PD-L1 TPS ≥1%: A report from a multicenter, open-label, phase II basket trial
    Ren, S.
    Wang, X.
    Han, B.
    Pan, Y.
    Zhao, J.
    Cheng, Y.
    Hu, S.
    Liu, T.
    Li, Y.
    Cheng, Y.
    Feng, J.
    Yi, S.
    Gu, S.
    Gao, S.
    Luo, Y.
    Liu, Y.
    Liu, C.
    Duan, H.
    Zhou, C.
    Fan, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S66 - S67
12345